Drug Information

Drug General Information
Drug ID
D0P9RF
Former ID
DAP000371
Drug Name
Terazosin
Synonyms
Blavin; Flumarc; Fosfomic; Hytracin; Hytrin; Terazosabb; Terazosina; Terazosine; Terazosinum; Vasomet; Trazosin HCl; A 45975; Abbott 45975; A-45975; Hytrin (TN); Terazosabb (TN); Terazosin (INN); Terazosin [INN:BAN]; Terazosina [INN-Spanish]; Terazosine [INN-French]; Terazosinum [INN-Latin]; [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl](tetrahydrofuran-2-yl)methanone; [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(oxolan-2-yl)methanone; 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-((tetrahydro-2-furanyl)carbonyl)piperazine; 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(tetrahydro-2-furoyl)piperazine; 6,7-bis(methyloxy)-2-[4-(tetrahydrofuran-2-ylcarbonyl)piperazin-1-yl]quinazolin-4-amine; 6,7-dimethoxy-2-[4-(tetrahydrofuran-2-ylcarbonyl)piperazin-1-yl]quinazolin-4-amine
Drug Type
Small molecular drug
Indication Benign prostatic hyperplasia [ICD9: 600; ICD10:N40] Approved [538289], [542324]
Therapeutic Class
Anticancer Agents
Company
Abbott Laboratories
Structure
Download
2D MOL

3D MOL
Formula
C19H25N5O4
InChI
InChI=1S/C19H25N5O4/c1-26-15-10-12-13(11-16(15)27-2)21-19(22-17(12)20)24-7-5-23(6-8-24)18(25)14-4-3-9-28-14/h10-11,14H,3-9H2,1-2H3,(H2,20,21,22)
InChIKey
VCKUSRYTPJJLNI-UHFFFAOYSA-N
CAS Number
CAS 63590-64-7
PubChem Compound ID
5401
PubChem Substance ID
9337, 855611, 3206271, 5639778, 7980757, 8153320, 11466779, 11467899, 11486437, 14805011, 29224453, 46509129, 47285410, 47583257, 47953972, 48104698, 48328570, 48416598, 49698629, 50011223, 50085853, 50104877, 56464178, 57322756, 79795430, 85209414, 85788394, 90340975, 92309317, 92710520, 92729635, 93625098, 96025253, 103185057, 103941452, 104170187, 104309137, 117762845, 121362449, 124750263, 124800293, 124881671, 124881672, 125325415, 125355205, 126631797, 126685615, 129455086, 131549269, 134337681
ChEBI ID
ChEBI:9445
SuperDrug ATC ID
G04CA03
SuperDrug CAS ID
cas=063590647
Target and Pathway
Target(s) Alpha-1D adrenergic receptor Target Info Antagonist [535079], [535647]
KEGG Pathway Calcium signaling pathway
cGMP-PKG signaling pathway
Neuroactive ligand-receptor interaction
Adrenergic signaling in cardiomyocytes
Vascular smooth muscle contraction
Salivary secretion
NetPath Pathway IL2 Signaling Pathway
Reactome Adrenoceptors
G alpha (q) signalling events
G alpha (12/13) signalling events
WikiPathways Monoamine GPCRs
Calcium Regulation in the Cardiac Cell
GPCRs, Class A Rhodopsin-like
Gastrin-CREB signalling pathway via PKC and MAPK
GPCR ligand binding
GPCR downstream signaling
GPCRs, Other
References
Ref 538289FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 074823.
Ref 542324(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7302).
Ref 535079Overexpression of the alpha1B-adrenergic receptor causes apoptotic neurodegeneration: multiple system atrophy. Nat Med. 2000 Dec;6(12):1388-94.
Ref 535647Induction of prostate apoptosis by alpha1-adrenoceptor antagonists: mechanistic significance of the quinazoline component. Prostate Cancer Prostatic Dis. 2002;5(2):88-95.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.